Comparing AI-Guided Minimally Invasive Hematoma Aspiration With Medical Treatment for Moderate Supratentorial Intracerebral Hemorrhage

What this Trial Is About

Researchers are investigating treatment options for patients with spontaneous supratentorial intracerebral hemorrhage ICH who have a moderate hematoma volume between 20 and 50 mL. The study aims to compare the clinical effectiveness and safety of two minimally invasive approaches AI-assisted, navigation-guided hematoma aspiration versus targeted pharmacological therapy. This multicenter randomized controlled trial seeks to provide evidence to guide treatment decisions and improve individualized care for patients with this serious stroke condition. Participants will be randomly assigned to one of two groups. The first group undergoes AI-assisted hematoma aspiration, where AI algorithms help guide precise catheter placement through a minimally invasive burr-hole procedure, performed under local or general anesthesia. The second group receives conservative pharmacological treatment aimed at promoting hematoma resolution and neuroprotection. Both groups will receive standardized supportive neurocritical care, including blood pressure and intracranial pressure management. During the study, patients will be monitored with brain imaging, neurological assessments, and functional evaluations using tools such as the modified Rankin Scale mRS at 6 months, Glasgow Coma Scale GCS, and NIH Stroke Scale NIHSS. Researchers will track hematoma resolution, complications, mortality, quality of life, and healthcare resource use. Follow-up lasts 6 months post-treatment, with independent evaluators assessing outcomes to ensure objective analysis.

AI-Guided Hematoma Aspiration vs. Conservative Treatment for Spontaneous ICH